Page last updated: 2024-11-05

palmatine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Palmatine is an alkaloid found in various plants, including Corydalis, Thalictrum, and Stephania species. It exhibits a wide range of pharmacological activities, including anti-inflammatory, analgesic, anti-cancer, and neuroprotective effects. Palmatine is known to inhibit the activity of several enzymes and receptors, including phosphodiesterase, protein kinase C, and the nicotinic acetylcholine receptor. Its synthesis involves complex multi-step reactions starting from naturally occurring precursors like berberine. Palmatine is being extensively studied for its potential therapeutic applications in treating various conditions such as inflammatory bowel disease, Alzheimer's disease, and cancer. The complex structure and pharmacological properties of palmatine make it an interesting target for further research in drug development.'

burasaine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID19009
CHEMBL ID274189
CHEMBL ID206106
CHEBI ID16096
SCHEMBL ID562120
MeSH IDM0046941

Synonyms (95)

Synonym
BSPBIO_000398
c21h22no4
BRD-K58466253-003-04-1
CHEBI:16096 ,
2,3,9,10-tetramethoxy-5,6-dihydroisoquino[3,2-a]isoquinolinium
7,8,13,13a-tetrahydro-2,3,9,10-tetramethoxyberbinium
DIVK1C_006834
DIVK1C_006715
NCI60_001757
SDCCGMLS-0066652.P001
berbinium, 7,8,13,13a-tetrahydro-2,3,9,10-tetramethoxy-
dibenzo(a,g)quinolizinium, 5,6-dihydro-2,3,9,10-tetramethoxy-
palmatin
5,6-dihydro-2,3,9,10-tetramethoxydibenzo(a,g)quinolizinium
brn 1555498
SPECTRUM_001849
cas-3486-67-7
NCGC00016631-01
BSPBIO_002629
BPBIO1_000438
burasaine
dibenzo[a,g]quinolizinium, 5,6-dihydro-2,3,9,10-tetramethoxy-
2,3,9,10-tetramethoxy-5,6-dihydroisoquinolino[3,2-a]isoquinolin-7-ium
o,o-dimethyldemethyleneberberine
berbericinine
SPECTRUM5_000684
PRESTWICK2_000579
PRESTWICK3_000579
7,8,13,13a-tetradehydro-2,3,9,10-tetramethoxyberbinium
5,6-dihydro-2,3,9,10-tetramethoxy-dibenzo[a,g]quinolizinium
5,6-dihydro-2,3,9,10-tetramethoxydibenzo[a,g]quinolizinium
palmatine ,
C05315
3486-67-7
KBIO2_007496
KBIOSS_002363
KBIO3_001854
KBIO2_002360
KBIO1_001778
KBIOGR_001469
KBIO2_004928
KBIO1_001659
PRESTWICK1_000579
SPECTRUM2_000608
SPECTRUM4_001005
SPECTRUM3_000907
SPBIO_002617
PRESTWICK0_000579
SPECPLUS_000619
SPECPLUS_000738
SPBIO_000516
SPECTRUM5_001860
gnf-pf-4086 ,
CHEMBL274189 ,
2,3,9,10-tetramethoxy-5,6-dihydroisoquinolino[2,1-b]isoquinolin-7-ium
STK801361
bdbm50292332
2,3,9,10-tetramethoxy-5,6-dihydro-isoquino[3,2-a]isoquinolinylium; chloride
2,3,9,10-tetramethoxy-5,6-dihydro-isoquino[3,2-a]isoquinolinylium
AKOS005612997
palmatine ion
palmatine cation
palmitine
CHEMBL206106
A822452
S3769
NCGC00016631-03
NCGC00016631-02
g50c034217 ,
5-21-06-00202 (beilstein handbook reference)
unii-g50c034217
FT-0603638
palmatine [inci]
palmatine [mi]
palmatine (negative marker) (constituent of goldenseal) [dsc]
palmatine [who-dd]
SCHEMBL562120
BBL028417
DTXSID9048065 ,
Q-100422
SR-01000841226-5
sr-01000841226
AC-7992
QUCQEUCGKKTEBI-UHFFFAOYSA-N
hindarinine
palmatine (negative marker) (constituent of goldenseal)
dtxcid0028036
2,3,9,10-tetramethoxy-5,6-dihydroisoquino(3,2-a)isoquinolinium
HY-N0110A
Q6634283
BRD-K58466253-003-07-4
HMS3885G04
palmatine-chloride
CCG-268056
CS-0013950

Research Excerpts

Overview

Palmatine (PAL) is an isoquinoline alkaloid derived from Fibraureae caulis Pierre that has been used to relieve inflammatory diseases like ulcerative colitis (UC) Palmatine originated from ancient Chinese herbal medicine Cortex Phellodendri Amurensis (CPA), which has long been applied to treat hyperuricemia (HUA)-related diseases. Pal matine is a main chemical component of Yajieshaba, which has been found to effectively alleviate the symptoms of food allergy.

ExcerptReferenceRelevance
"Palmatine is a naturally occurring isoquinoline alkaloid that has been reported to display neuroprotective effects against amyloid-"( Neuroprotective Effects of Palmatine via the Enhancement of Antioxidant Defense and Small Heat Shock Protein Expression in A
Cheng, Q; Jia, W; Luo, X; Peng, Q; Qiao, A; Su, Q; Wang, Y; Zhang, J, 2021
)
2.36
"Palmatine (PAL) is an isoquinoline alkaloid derived from Fibraureae caulis Pierre that has been used to relieve inflammatory diseases like ulcerative colitis (UC). "( 8-Oxypalmatine, a novel oxidative metabolite of palmatine, exhibits superior anti-colitis effect via regulating Nrf2 and NLRP3 inflammasome.
Ai, G; Cheng, J; Huang, X; Li, M; Ma, X; Su, Z; Wu, X; Xie, J; Zhan, R; Zhang, H, 2022
)
2.68
"Palmatine (Pal) is a major bioactive alkaloid originated from ancient Chinese herbal medicine Cortex Phellodendri Amurensis (CPA), which has long been applied to treat hyperuricemia (HUA)-related diseases. "( Hypouricemic and nephroprotective effects of palmatine from Cortex Phellodendri Amurensis: A uric acid modulator targeting Keap1-Nrf2/NLRP3 axis.
Ai, G; Chen, J; Dou, Y; Huang, R; Qin, Z; Su, Z; Wu, X; Xie, J; Yang, X; Zhong, L, 2023
)
2.61
"Palmatine (PAL) is a naturally occurring (Coptidis rhizome) isoquinoline alkaloid that belongs to the class of protoberberines and has a wide spectrum of pharmacological and biological effects."( Palmatine, a natural alkaloid, attenuates memory deficits and neuroinflammation in mice submitted to permanent focal cerebral ischemia.
Bezerra, JR; da Silva, ATA; de Andrade, GM; de Barros Viana, GS; de Sousa Nascimento, T; de Sousa Neves, JC; Fonteles, AA; Gomes, JMP; Lima, FAV; Neves, KRT; Oliveira, AV; Oriá, RB; Parente, ACB; Pereira, JF; Pires, RC; Tavares, J, 2023
)
3.07
"Palmatine (PAL) is a main chemical component of Yajieshaba, which has been found to effectively alleviate the symptoms of food allergy."( Palmatine treats urticaria by reducing inflammation and increasing autophagy.
Duan, X; Xiao, T; Yang, L; Yu, X, 2023
)
3.07
"Palmatine (PAL) is a natural isoquinoline alkaloid that has been widely used in the pharmaceutical field. "( Palmatine regulates bile acid cycle metabolism and maintains intestinal flora balance to maintain stable intestinal barrier.
Ning, Y; Xin, R; Xu, F; Yao, F, 2020
)
3.44
"Palmatine is a naturally occurring isoquinoline alkaloid with various pharmacological properties. "( Palmatine as an Agent Against Metabolic Syndrome and Its Related Complications: A Review.
Chin, KY; Ekeuku, SO; Pang, KL, 2020
)
3.44
"Palmatine is a natural isoquinoline alkaloid widely found in traditional Chinese medicines. "( Pharmacokinetics, tissue distribution and plasma protein binding rate of palmatine following intragastric and intravenous administration in rats using liquid chromatography tandem mass spectrometry.
Song, Y; Wang, K; Wei, M; Wei, T; Wei, X; Xiao, T, 2021
)
2.3
"Palmatine is a natural isoquinoline alkaloid and has been widely used in pharmaceutical field. "( Palmatine: A review of its pharmacology, toxicity and pharmacokinetics.
Li, X; Liao, Y; Liu, L; Long, J; Song, J; Zhong, L, 2019
)
3.4
"Palmatine is a protoberberine alkaloid separated from several plants and application as an anti-inflammatory and antibacterial agent in the therapy of gastrointestinal and genitourinary disorder. "( Size-tunable Au@Ag nanoparticles for colorimetric and SERS dual-mode sensing of palmatine in traditional Chinese medicine.
Dina, NE; Gao, Y; Gherman, AMR; Hu, Z; Jian, J; Jiang, Z; Liang, X; Ning, Z; Wang, J; Wang, Z; Wu, J; Yang, X; Yang, Z; Zhao, Q; Zhao, T; Zhou, H, 2019
)
2.18
"Palmatine (PM) is a potent anti-infective agent used to treat eye diseases. "( Cationic lipid emulsions as potential bioadhesive carriers for ophthalmic delivery of palmatine.
Lu, G; Xiang, C; Yin, J, 2016
)
2.1
"Palmatine is an isoquinoline alkaloid from Coptis chinensis, an herbal medicine used to treat various inflammatory diseases such as gastritis, edema and dermatitis. "( Palmatine attenuates D-galactosamine/lipopolysaccharide-induced fulminant hepatic failure in mice.
Choi, JS; Jung, HA; Jung, JY; Kang, JW; Kim, JK; Kim, YS; Lee, SM; Lee, WC; Oh, WY, 2010
)
3.25
"Palmatine is an isoquinoline alkaloid that has been widely used in China for the treatment of various inflammatory diseases such as gynecological inflammation, bacillary dysentery, enteritis, respiratory tract infection, urinary infection, etc. "( Identification of palmatine and its metabolites in rat urine by liquid chromatography/tandem mass spectrometry.
Chen, H; Chen, Y; Han, F; Peng, Z; Zhu, M, 2007
)
2.12
"Palmatine is an alkaloid found in various plants exhibiting a broad spectrum of antibiotic activity in humans."( Fast fluorescent staining of protein in sodium dodecyl sulfate polyacrylamide gels by palmatine.
Choi, JK; Cong, WT; Hwang, SY; Jin, LT, 2008
)
1.29

Effects

Palmatine (PLT) has a variety of biological functions, such as broad-spectrum antibacterial action. Palmatine has a significant restorative effect on the cell viability of Raw264.7 in a concentration of 0.1 mg/ml.

Palmatine (PLT) has a variety of biological functions, such as broad-spectrum antibacterial action, neuroprotective, antioxidant stress, and antiviral and anti-inflammatory activities. Palmatine can significantly induce Raw264.7 cells to secret IL-6 and IL1-β in a concentration-dependent manner, but it has not obvious impact on NO and TNF-α.

ExcerptReferenceRelevance
"Palmatine (PLT) has a variety of biological functions, such as broad-spectrum antibacterial action, neuroprotective, antioxidant stress, and antiviral and anti-inflammatory activities."( Palmatine attenuates hepatocyte injury by promoting autophagy via the AMPK/mTOR pathway after alcoholic liver disease.
Ba, TT; Fu, QC; Lin, GS; Yu, HX; Zhao, MM; Zhao, SY, 2022
)
2.89
"Palmatine has a significant restorative effect on the cell viability of Raw264.7 in a concentration of 0.1 mg/ml."( Network pharmacology and molecular docking integrated strategy to investigate the pharmacological mechanism of palmatine in Alzheimer's disease.
Chen, W; Du, R; He, Z; Pei, H; Zeng, J, 2022
)
1.65
"Palmatine has a wide range of pharmacological effects and anti-inflammatory function. "( Palmatine attenuates LPS-induced inflammatory response in mouse mammary epithelial cells through inhibiting ERK1/2, P38 and Akt/NF-кB signalling pathways.
Fu, S; Guo, W; Hu, G; Liu, J; Ma, H; Wang, J; Xie, S; Yang, Z; Zhang, Y, 2021
)
3.51
"Palmatine has a wide spectrum of pharmacological effects, including anti-cancer, anti-oxidation, anti-inflammatory, neuroprotection, anti-bacterial, anti-viral and regulating blood lipids."( Palmatine: A review of its pharmacology, toxicity and pharmacokinetics.
Li, X; Liao, Y; Liu, L; Long, J; Song, J; Zhong, L, 2019
)
2.68
"Palmatine (PLT) has a variety of biological functions, such as broad-spectrum antibacterial action, neuroprotective, antioxidant stress, and antiviral and anti-inflammatory activities."( Palmatine attenuates hepatocyte injury by promoting autophagy via the AMPK/mTOR pathway after alcoholic liver disease.
Ba, TT; Fu, QC; Lin, GS; Yu, HX; Zhao, MM; Zhao, SY, 2022
)
2.89
"Palmatine has no significant effect on Raw264.7 cells viability within 0.05 mg/ml, Palmatine can significantly induce Raw264.7 cells to secret IL-6 and IL1-β in a concentration-dependent manner, but it has not obvious impact on NO and TNF-α."( Network pharmacology and molecular docking integrated strategy to investigate the pharmacological mechanism of palmatine in Alzheimer's disease.
Chen, W; Du, R; He, Z; Pei, H; Zeng, J, 2022
)
1.65
"Palmatine has neuroprotective effects. "( Network pharmacology and molecular docking integrated strategy to investigate the pharmacological mechanism of palmatine in Alzheimer's disease.
Chen, W; Du, R; He, Z; Pei, H; Zeng, J, 2022
)
2.38
"Palmatine has a wide range of pharmacological effects and anti-inflammatory function. "( Palmatine attenuates LPS-induced inflammatory response in mouse mammary epithelial cells through inhibiting ERK1/2, P38 and Akt/NF-кB signalling pathways.
Fu, S; Guo, W; Hu, G; Liu, J; Ma, H; Wang, J; Xie, S; Yang, Z; Zhang, Y, 2021
)
3.51
"Palmatine has a wide spectrum of pharmacological effects, including anti-cancer, anti-oxidation, anti-inflammatory, neuroprotection, anti-bacterial, anti-viral and regulating blood lipids."( Palmatine: A review of its pharmacology, toxicity and pharmacokinetics.
Li, X; Liao, Y; Liu, L; Long, J; Song, J; Zhong, L, 2019
)
2.68

Actions

Palmatine prevents the increase of serum TNF-alpha and augmented that of serum IL-10. Palmatine plays a significant role in sedation and hypnosis, which may be associated with an increase of intra-cerebral 5-HT.

ExcerptReferenceRelevance
"Palmatine plays a significant role in sedation and hypnosis, which may be associated with the increase of intra-cerebral 5-HT."( Palmatine plays a role in sedation and hypnosis by increasing 5-hydroxytryptamine.
Du, J; Qiu, L; Qiu, M; Yu, Y; Zhu, Q, 2019
)
2.68
"Palmatine prevented the increase of serum TNF-alpha and augmented that of serum IL-10."( Palmatine attenuates D-galactosamine/lipopolysaccharide-induced fulminant hepatic failure in mice.
Choi, JS; Jung, HA; Jung, JY; Kang, JW; Kim, JK; Kim, YS; Lee, SM; Lee, WC; Oh, WY, 2010
)
2.52

Treatment

Palmatine treatment caused reduction in plasma AST, ALT, urine flow rate, creatinine clearance, renal and hapatic malondialdehyde, apoptosis. In palmatine-treated mice, RANKL and OPG expression decreased.

ExcerptReferenceRelevance
"Palmatine treatment down-regulated the expression of chaperone proteins CALR and GRP78 and up-regulated the expression of Prdx4, PDIA2/3, GST, and ALB."( Palmatine Inhibits Up-Regulation of GRP78 and CALR Protein in an STZ-Induced Diabetic Rat Model.
Chan, HK; Ekeuku, SO; Eluri, K; Froemming, GRA; Okechukwu, PN, 2021
)
2.79
"Palmatine treatment significantly attenuated ISO-induced hypertrophy in rats and elicited remarkable repressions in ANP, BNP, and HDAC2 transcriptions but not HDAC5."( Palmatine attenuates isoproterenol-induced pathological hypertrophy via selectively inhibiting HDAC2 in rats.
Liu, Y; Peng, W; Xu, Z; Yuan, Y, 2017
)
2.62
"Palmatine treatment caused reduction in plasma AST, ALT, urine flow rate, creatinine clearance, renal and hapatic malondialdehyde, apoptosis and increase in renal and hapatic glutathione, fractional excretion of Na and K, plasma BUN and creatinine in contrast to GM group."( Palmatine ameliorates nephrotoxicity and hepatotoxicity induced by gentamicin in rats.
Abedloo, R; Esmaili, S; Khaksari, M; Khastar, H, 2021
)
2.79
"In palmatine-treated mice, RANKL and OPG expression decreased."( Influence of Palmatine on Bone Metabolism in Ovariectomized Mice and Cytokine Secretion of Osteoblasts.
Hisamitsu, T; Ishikawa, S; Kusayanagi, H; Moue, T; Ogawa, Y; Sunagawa, M; Tajika, Y; Takashima, M; Tamaki, M; Zhang, M,
)
1.01
"With palmatine treatment, however, the dysplastic changes were greatly reduced in the small intestine and colon tissue."( Palmatine from Mahonia bealei attenuates gut tumorigenesis in ApcMin/+ mice via inhibition of inflammatory cytokines.
Dong, CL; Guo, CR; He, X; Li, H; Ma, WK; Wang, CZ; Yu, CH; Yuan, CS; Zhang, CF, 2016
)
2.33
"Treatment with palmatine (2 and 20 mg/kg) reduced infarct size and neurological deficits and prevented working and aversive memory deficits in ischemic mice."( Palmatine, a natural alkaloid, attenuates memory deficits and neuroinflammation in mice submitted to permanent focal cerebral ischemia.
Bezerra, JR; da Silva, ATA; de Andrade, GM; de Barros Viana, GS; de Sousa Nascimento, T; de Sousa Neves, JC; Fonteles, AA; Gomes, JMP; Lima, FAV; Neves, KRT; Oliveira, AV; Oriá, RB; Parente, ACB; Pereira, JF; Pires, RC; Tavares, J, 2023
)
2.69
"Pretreatment with palmatine shifted the dose-response curves of PE both rightwards and downwards in a dose-dependent manner."( Effects of palmatine on isometric force and intracellular calcium levels of arterial smooth muscle.
Chang, YL; Hsieh, MT; Jiang, MJ; Usami, S, 1999
)
1.02

Toxicity

ExcerptReferenceRelevance
" The presence of Goldenseal root powder in dietary supplements and the topical application of Goldenseal preparations raise the possibility that an adverse phototoxic reaction may result from an interaction between its constituent alkaloids and light in exposed tissues."( Photochemistry and photocytotoxicity of alkaloids from Goldenseal (Hydrastis canadensis L.). 2. Palmatine, hydrastine, canadine, and hydrastinine.
Bilski, P; Chignell, CF; He, YY; Inbaraj, JJ; Kukielczak, BM; Sik, RH, 2006
)
0.55

Pharmacokinetics

The fully validated LC-MS/MS method has been successfully applied to the pharmacokinetic study of berberine, palmatine and jatrorrhizine in rat plasma. Pharmacokinetic studies have demonstrated that glucuronidation and sulfation are the main metabolic pathways of Palmatine.

ExcerptReferenceRelevance
" The validated method was used to study the pharmacokinetic profile of berberine and palmatine in rat plasma after oral administration of Huang-Lian-Jie-Du decoction."( Simultaneous determination of berberine and palmatine in rat plasma by HPLC-ESI-MS after oral administration of traditional Chinese medicinal preparation Huang-Lian-Jie-Du decoction and the pharmacokinetic application of the method.
Liang, Y; Liu, XD; Lu, T; Song, J; Wang, GJ; Xie, L, 2006
)
0.82
" The fully validated LC-MS/MS method has been successfully applied to the pharmacokinetic study of berberine, palmatine and jatrorrhizine in rat plasma after oral administration of coptis-evodia herb couple."( Simultaneous determination of berberine, palmatine and jatrorrhizine by liquid chromatography-tandem mass spectrometry in rat plasma and its application in a pharmacokinetic study after oral administration of coptis-evodia herb couple.
Bi, K; Deng, Y; Li, S; Liao, Q; Pan, B; Xie, Z, 2008
)
0.82
" The validated method was successfully applied to a pharmacokinetic study of tetrahydropalmatine, protopine and palmatine in rats after oral administration of Rhizoma Corydalis Decumbentis extract."( Simultaneous determination of tetrahydropalmatine, protopine, and palmatine in rat plasma by LC-ESI-MS and its application to a pharmacokinetic study.
Chang, X; Guo, T; He, Z; Ma, H; Pu, X; Wang, Y, 2009
)
0.84
" The validated method was applied in pharmacokinetic studies after oral administration of Yiqing Capsule and Gegen-Qinlian Tablet to rats."( Simultaneous determination of baicalin, baicalein, wogonin, berberine, palmatine and jatrorrhizine in rat plasma by liquid chromatography-tandem mass spectrometry and application in pharmacokinetic studies after oral administration of traditional Chinese
Cai, F; Chen, W; Feng, J; Jiang, B; Tao, X; Wei, H; Xu, W, 2010
)
0.59
" Finally, the method was successfully applied to a pharmacokinetic study of mitoxantrone in rats following intravenous administration."( Determination of mitoxantrone in rat plasma by liquid chromatography-tandem mass spectrometry method: Application to a pharmacokinetic study.
He, Z; Ling, G; Pu, X; Sun, J; Sun, Y; Wang, Z; Zhang, P, 2010
)
0.36
" There is limited information available for differences of pharmacokinetic properties of San-Huang formula between normal and metabolic syndrome rats."( Pharmacokinetic comparisons of berberine and palmatine in normal and metabolic syndrome rats.
Jiao, Z; Li, ZD; Liu, QF; Shi, XJ; Wang, B; Zhong, MK, 2014
)
0.66
" Various pharmacokinetic parameters were estimated from the plasma concentration versus time data using non-compartmental methods."( Pharmacokinetic comparisons of berberine and palmatine in normal and metabolic syndrome rats.
Jiao, Z; Li, ZD; Liu, QF; Shi, XJ; Wang, B; Zhong, MK, 2014
)
0.66
" A sensitive, specific and validated ultra-performance liquid chromatography-tandem mass spectrometric method was developed to investigate the pharmacokinetic profiles of BBR and PMT in rat plasma and in situ intestinal perfusion solution."( Comparative pharmacokinetics of active alkaloids after oral administration of Rhizoma Coptidis extract and Wuji Wan formulas in rat using a UPLC-MS/MS method.
Chen, Y; Dong, Y; Gong, Z; Li, Y; Wang, Y; Weng, X; Yang, Q; Zhang, R; Zhu, X, 2015
)
0.42
" The results showed that the pharmacokinetic behaviors of the alkaloids were different although their chemical structures were similar."( Pharmacochemistry and integrated pharmacokinetics of six alkaloids after oral administration of huang-lian-jie-du-tang decoction.
Liu, JX; Ma, ZT; Yang, XW; Zhang, Y, 2014
)
0.4
" Significant pharmacokinetic differences were observed between the African and Chinese subjects."( Pharmacokinetics of a multicomponent herbal preparation in healthy Chinese and African volunteers.
Alolga, RN; Chen, Y; Fan, Y; Lelu Kakila, J; Li, J; Li, P; Qi, LW; Zhang, G; Zhao, YJ, 2015
)
0.42
" After the concentration changes of palmatine and jatrorrhizine in the plasma of rats were determined by RP-HPLC, pharmacokinetic parameters and oral bioavailability were calculated by 3P97 software."( [Pharmacokinetics and oral bioavailability of palmatine and jatrorrhizine in Huangteng in rats].
Gao, YG; He, ZM; Li, GF; Yang, H; Zhang, LX; Zhao, Y; Zheng, JY; Zhu, HY, 2017
)
0.99
" Pharmacokinetic studies have demonstrated that glucuronidation and sulfation are the main metabolic pathways of palmatine."( Palmatine: A review of its pharmacology, toxicity and pharmacokinetics.
Li, X; Liao, Y; Liu, L; Long, J; Song, J; Zhong, L, 2019
)
2.17
" The method was successfully applied to a comparative pharmacokinetic study of GQLD in normal and pyrexia rats."( Screening of differential components of Gegenqinlian decoction and their comparative pharmacokinetics in normal and pyrexia rats using UHPLC-FT-ICR-MS and UHPLC-MS/MS.
Cui, Y; Li, R; Liu, T; Yu, Z; Zhang, N; Zhao, Y, 2021
)
0.62
" Non-compartmental pharmacokinetic parameters indicated that there is a significant difference in the apparent distribution volume and half-life between intragastric and intravenous administration modes."( Pharmacokinetics, tissue distribution and plasma protein binding rate of palmatine following intragastric and intravenous administration in rats using liquid chromatography tandem mass spectrometry.
Song, Y; Wang, K; Wei, M; Wei, T; Wei, X; Xiao, T, 2021
)
0.85

Compound-Compound Interactions

ExcerptReferenceRelevance
" Therefore, ultrafiltration liquid chromatography combined with high-speed countercurrent chromatography is not only a powerful tool for screening and isolating α-glucosidase and xanthine oxidase inhibitors in complex samples but is also a useful platform for discovering bioactive compounds for the prevention and treatment of diabetes mellitus and gout."( Ultrafiltration liquid chromatography combined with high-speed countercurrent chromatography for screening and isolating potential α-glucosidase and xanthine oxidase inhibitors from Cortex Phellodendri.
Guo, L; Li, S; Liu, C; Ma, B; Qin, Y; Ren, J; Tang, Y; Wang, J; Wang, Y; Yang, X; Zhang, Y, 2014
)
0.4
" In this work, we constructed an optimized method for quality evaluation and species discrimination of CR by ion-pairing high performance liquid chromatography (IP-HPLC) combined with response surface methodology (RSM)."( Construction of an optimized method for quality evaluation and species discrimination of Coptidis Rhizoma by ion-pair high performance liquid chromatography combined with response surface methodology.
Jiang, Y; Li, HJ; Li, P; Lu, J; Ni, H; Wu, TJ, 2018
)
0.48
"In order to develop a direct and reliable method for discovering lead compounds from traditional Chinese medicines (TCMs), a comparative online ligand fishing platform was developed using immobilized capillary enzyme reactors (ICERs) in combination with liquid chromatography-mass spectrometry (LC-MS)."( Online screening of acetylcholinesterase inhibitors in natural products using monolith-based immobilized capillary enzyme reactors combined with liquid chromatography-mass spectrometry.
Jiang, Z; Kool, J; Somsen, GW; Wang, L; Wang, Q; Zhang, T; Zhang, Y; Zhao, Y, 2018
)
0.48

Bioavailability

In situ single-pass perfused rat intestinal model was used. Concentrations of berberine and palmatine were determined by HPLC. The drug absorption rate constant (K(a) and apparent absorption coefficient (P(app) were tested to evaluate their absorption characteristics.

ExcerptReferenceRelevance
" The orally bioavailable lead imidazolopiperazine confers complete causal prophylactic protection (15 milligrams/kilogram) in rodent models of malaria and shows potent in vivo blood-stage therapeutic activity."( Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
Barnes, SW; Bonamy, GM; Bopp, SE; Borboa, R; Bright, AT; Chatterjee, A; Che, J; Cohen, S; Dharia, NV; Diagana, TT; Fidock, DA; Froissard, P; Gagaring, K; Gettayacamin, M; Glynne, RJ; Gordon, P; Groessl, T; Kato, N; Kuhen, KL; Lee, MC; Mazier, D; McNamara, CW; Meister, S; Nagle, A; Nam, TG; Plouffe, DM; Richmond, W; Roland, J; Rottmann, M; Sattabongkot, J; Schultz, PG; Tuntland, T; Walker, JR; Winzeler, EA; Wu, T; Zhou, B; Zhou, Y, 2011
)
0.37
"In situ single-pass perfused rat intestinal model was used and the concentrations of berberine and palmatine were determined by HPLC, the drug absorption rate constant (K(a)) and apparent absorption coefficient (P(app)) were tested to evaluate their absorption characteristics."( [Studies on intestinal absorption of alkaloids in Coptis chinensis by in situ single-pass perfused rat intestinal model].
Chen, Y; Li, Y; Men, W; Wang, Y; Weng, X; Yang, Q; Zhu, X; Zou, L, 2011
)
0.59
" Particularly, the oral bioavailability of PMT in WJW formula 1 was significantly increased."( Comparative pharmacokinetics of active alkaloids after oral administration of Rhizoma Coptidis extract and Wuji Wan formulas in rat using a UPLC-MS/MS method.
Chen, Y; Dong, Y; Gong, Z; Li, Y; Wang, Y; Weng, X; Yang, Q; Zhang, R; Zhu, X, 2015
)
0.42
" After the concentration changes of palmatine and jatrorrhizine in the plasma of rats were determined by RP-HPLC, pharmacokinetic parameters and oral bioavailability were calculated by 3P97 software."( [Pharmacokinetics and oral bioavailability of palmatine and jatrorrhizine in Huangteng in rats].
Gao, YG; He, ZM; Li, GF; Yang, H; Zhang, LX; Zhao, Y; Zheng, JY; Zhu, HY, 2017
)
0.99

Dosage Studied

Proteomics was used to analyse differentially expressed proteins (DEPs) in goat endometrial epithelial cells (EECs) stimulated by lipopolysaccharide. Pretreatment with palmatine shifted the dose-response curves of PE both rightwards and downwards in a dose-dependent manner.

ExcerptRelevanceReference
" Pretreatment with palmatine shifted the dose-response curves of PE both rightwards and downwards in a dose-dependent manner."( Effects of palmatine on isometric force and intracellular calcium levels of arterial smooth muscle.
Chang, YL; Hsieh, MT; Jiang, MJ; Usami, S, 1999
)
1.02
"In the different dosage of extractive Rhizoma Coptidis, the absorption of BER and PAL Conforms to the zero order rate process at the different intestine, and is the passive absorption."( [Absorption of extractive Rhizoma Coptidis in rat everted gut scas].
Bao, TD; Dong, Y; Li, YJ; Pan, GF; Weng, XG; Yang, Q; Zhang, YF; Zhu, XX, 2008
)
0.35
"We used proteomics to analyse differentially expressed proteins (DEPs) in goat endometrial epithelial cells (EECs) stimulated by lipopolysaccharide (LPS, 5 μg/mL, the dosage can induce inflammatory response, according to our previous study) for 12 h and then treated with palmatine (80 μg/mL) for 8 h; the dosage was selected based on MTT assay."( Comparative proteomics analysis indicates that palmatine contributes to transepithelial migration by regulating cellular adhesion.
Dongan, C; Feng, Y; Hui, W; Jiongjie, H; Ruihua, X; Shidong, Z; Yan, S, 2020
)
0.99
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
berberine alkaloid
organic heterotetracyclic compound
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
palmatine biosynthesis016
berberine biosynthesis032
palmatine biosynthesis09
berberine biosynthesis132

Protein Targets (13)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency12.55940.140911.194039.8107AID2451
USP1 protein, partialHomo sapiens (human)Potency39.81070.031637.5844354.8130AID504865
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency12.58930.00137.762544.6684AID914; AID915
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency12.58930.00207.533739.8107AID891
lamin isoform A-delta10Homo sapiens (human)Potency0.50120.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Lysine-specific histone demethylase 1AHomo sapiens (human)IC50 (µMol)12.23000.00312.16029.6000AID1845962
NeuraminidaseInfluenza A virus (A/USSR/90/1977(H1N1))IC50 (µMol)31.45000.00140.00550.0130AID1167295; AID1167296
CholinesteraseHomo sapiens (human)IC50 (µMol)100.00000.00001.559910.0000AID1537270
Genome polyproteinWest Nile virusIC50 (µMol)96.00000.10504.57628.9000AID1168662
Tyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)IC50 (µMol)234.00000.00053.49849.7600AID1416210
AcetylcholinesteraseHomo sapiens (human)IC50 (µMol)1.70000.00000.933210.0000AID1537269
Prolyl endopeptidaseHomo sapiens (human)IC50 (µMol)200.00000.00111.98969.7500AID1537274
Histone acetyltransferase p300Homo sapiens (human)IC50 (µMol)1.05000.26004.00008.5000AID1727405
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (137)

Processvia Protein(s)Taxonomy
regulation of double-strand break repair via homologous recombinationLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of protein ubiquitinationLysine-specific histone demethylase 1AHomo sapiens (human)
regulation of protein localizationLysine-specific histone demethylase 1AHomo sapiens (human)
cellular response to UVLysine-specific histone demethylase 1AHomo sapiens (human)
cellular response to gamma radiationLysine-specific histone demethylase 1AHomo sapiens (human)
DNA repair-dependent chromatin remodelingLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of transcription by RNA polymerase IILysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of neuroblast proliferationLysine-specific histone demethylase 1AHomo sapiens (human)
regulation of transcription by RNA polymerase IILysine-specific histone demethylase 1AHomo sapiens (human)
protein demethylationLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of epithelial to mesenchymal transitionLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of neuron projection developmentLysine-specific histone demethylase 1AHomo sapiens (human)
cerebral cortex developmentLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of protein bindingLysine-specific histone demethylase 1AHomo sapiens (human)
neuron maturationLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of DNA bindingLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of DNA-binding transcription factor activityLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of DNA damage response, signal transduction by p53 class mediatorLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of cell sizeLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of DNA-templated transcriptionLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of transcription by RNA polymerase IILysine-specific histone demethylase 1AHomo sapiens (human)
guanine metabolic processLysine-specific histone demethylase 1AHomo sapiens (human)
muscle cell developmentLysine-specific histone demethylase 1AHomo sapiens (human)
regulation of androgen receptor signaling pathwayLysine-specific histone demethylase 1AHomo sapiens (human)
response to fungicideLysine-specific histone demethylase 1AHomo sapiens (human)
cellular response to cAMPLysine-specific histone demethylase 1AHomo sapiens (human)
regulation of DNA methylation-dependent heterochromatin formationLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of cold-induced thermogenesisLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of neural precursor cell proliferationLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of stem cell proliferationLysine-specific histone demethylase 1AHomo sapiens (human)
chromatin remodelingLysine-specific histone demethylase 1AHomo sapiens (human)
xenobiotic metabolic processCholinesteraseHomo sapiens (human)
learningCholinesteraseHomo sapiens (human)
negative regulation of cell population proliferationCholinesteraseHomo sapiens (human)
neuroblast differentiationCholinesteraseHomo sapiens (human)
peptide hormone processingCholinesteraseHomo sapiens (human)
response to alkaloidCholinesteraseHomo sapiens (human)
cocaine metabolic processCholinesteraseHomo sapiens (human)
negative regulation of synaptic transmissionCholinesteraseHomo sapiens (human)
response to glucocorticoidCholinesteraseHomo sapiens (human)
response to folic acidCholinesteraseHomo sapiens (human)
choline metabolic processCholinesteraseHomo sapiens (human)
acetylcholine catabolic processCholinesteraseHomo sapiens (human)
positive regulation of JUN kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
actin cytoskeleton organizationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of endocytosisTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of vascular endothelial growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulum unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of intracellular protein transportTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cellular response to unfolded proteinTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
platelet-derived growth factor receptor-beta signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor recyclingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of MAP kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of type I interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STATTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of protein tyrosine kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of hepatocyte growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of PERK-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylation involved in inactivation of protein kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of receptor catabolic processTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
acetylcholine catabolic process in synaptic cleftAcetylcholinesteraseHomo sapiens (human)
regulation of receptor recyclingAcetylcholinesteraseHomo sapiens (human)
osteoblast developmentAcetylcholinesteraseHomo sapiens (human)
acetylcholine catabolic processAcetylcholinesteraseHomo sapiens (human)
cell adhesionAcetylcholinesteraseHomo sapiens (human)
nervous system developmentAcetylcholinesteraseHomo sapiens (human)
synapse assemblyAcetylcholinesteraseHomo sapiens (human)
receptor internalizationAcetylcholinesteraseHomo sapiens (human)
negative regulation of synaptic transmission, cholinergicAcetylcholinesteraseHomo sapiens (human)
amyloid precursor protein metabolic processAcetylcholinesteraseHomo sapiens (human)
positive regulation of protein secretionAcetylcholinesteraseHomo sapiens (human)
retina development in camera-type eyeAcetylcholinesteraseHomo sapiens (human)
acetylcholine receptor signaling pathwayAcetylcholinesteraseHomo sapiens (human)
positive regulation of cold-induced thermogenesisAcetylcholinesteraseHomo sapiens (human)
proteolysisProlyl endopeptidaseHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone acetyltransferase p300Homo sapiens (human)
response to hypoxiaHistone acetyltransferase p300Homo sapiens (human)
somitogenesisHistone acetyltransferase p300Homo sapiens (human)
thigmotaxisHistone acetyltransferase p300Homo sapiens (human)
behavioral defense responseHistone acetyltransferase p300Homo sapiens (human)
stimulatory C-type lectin receptor signaling pathwayHistone acetyltransferase p300Homo sapiens (human)
regulation of glycolytic processHistone acetyltransferase p300Homo sapiens (human)
protein acetylationHistone acetyltransferase p300Homo sapiens (human)
internal protein amino acid acetylationHistone acetyltransferase p300Homo sapiens (human)
apoptotic processHistone acetyltransferase p300Homo sapiens (human)
canonical NF-kappaB signal transductionHistone acetyltransferase p300Homo sapiens (human)
nervous system developmentHistone acetyltransferase p300Homo sapiens (human)
heart developmentHistone acetyltransferase p300Homo sapiens (human)
skeletal muscle tissue developmentHistone acetyltransferase p300Homo sapiens (human)
learning or memoryHistone acetyltransferase p300Homo sapiens (human)
circadian rhythmHistone acetyltransferase p300Homo sapiens (human)
animal organ morphogenesisHistone acetyltransferase p300Homo sapiens (human)
regulation of autophagyHistone acetyltransferase p300Homo sapiens (human)
negative regulation of autophagyHistone acetyltransferase p300Homo sapiens (human)
macrophage derived foam cell differentiationHistone acetyltransferase p300Homo sapiens (human)
regulation of mitochondrion organizationHistone acetyltransferase p300Homo sapiens (human)
positive regulation of neuron projection developmentHistone acetyltransferase p300Homo sapiens (human)
N-terminal peptidyl-lysine acetylationHistone acetyltransferase p300Homo sapiens (human)
internal peptidyl-lysine acetylationHistone acetyltransferase p300Homo sapiens (human)
peptidyl-lysine acetylationHistone acetyltransferase p300Homo sapiens (human)
B cell differentiationHistone acetyltransferase p300Homo sapiens (human)
platelet formationHistone acetyltransferase p300Homo sapiens (human)
lung developmentHistone acetyltransferase p300Homo sapiens (human)
positive regulation of transforming growth factor beta receptor signaling pathwayHistone acetyltransferase p300Homo sapiens (human)
negative regulation of protein-containing complex assemblyHistone acetyltransferase p300Homo sapiens (human)
protein destabilizationHistone acetyltransferase p300Homo sapiens (human)
cellular response to nutrient levelsHistone acetyltransferase p300Homo sapiens (human)
cellular response to UVHistone acetyltransferase p300Homo sapiens (human)
multicellular organism growthHistone acetyltransferase p300Homo sapiens (human)
megakaryocyte developmentHistone acetyltransferase p300Homo sapiens (human)
swimmingHistone acetyltransferase p300Homo sapiens (human)
positive regulation of protein import into nucleusHistone acetyltransferase p300Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorHistone acetyltransferase p300Homo sapiens (human)
response to estrogenHistone acetyltransferase p300Homo sapiens (human)
positive regulation by host of viral transcriptionHistone acetyltransferase p300Homo sapiens (human)
fat cell differentiationHistone acetyltransferase p300Homo sapiens (human)
negative regulation of gluconeogenesisHistone acetyltransferase p300Homo sapiens (human)
transcription initiation-coupled chromatin remodelingHistone acetyltransferase p300Homo sapiens (human)
positive regulation of DNA-templated transcriptionHistone acetyltransferase p300Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIHistone acetyltransferase p300Homo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATHistone acetyltransferase p300Homo sapiens (human)
protein stabilizationHistone acetyltransferase p300Homo sapiens (human)
positive regulation of DNA-binding transcription factor activityHistone acetyltransferase p300Homo sapiens (human)
face morphogenesisHistone acetyltransferase p300Homo sapiens (human)
regulation of androgen receptor signaling pathwayHistone acetyltransferase p300Homo sapiens (human)
peptidyl-lysine propionylationHistone acetyltransferase p300Homo sapiens (human)
cellular response to L-leucineHistone acetyltransferase p300Homo sapiens (human)
regulation of tubulin deacetylationHistone acetyltransferase p300Homo sapiens (human)
peptidyl-lysine crotonylationHistone acetyltransferase p300Homo sapiens (human)
peptidyl-lysine butyrylationHistone acetyltransferase p300Homo sapiens (human)
regulation of cellular response to heatHistone acetyltransferase p300Homo sapiens (human)
regulation of signal transduction by p53 class mediatorHistone acetyltransferase p300Homo sapiens (human)
positive regulation of TORC1 signalingHistone acetyltransferase p300Homo sapiens (human)
positive regulation of T-helper 17 cell lineage commitmentHistone acetyltransferase p300Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (77)

Processvia Protein(s)Taxonomy
telomeric DNA bindingLysine-specific histone demethylase 1AHomo sapiens (human)
p53 bindingLysine-specific histone demethylase 1AHomo sapiens (human)
chromatin bindingLysine-specific histone demethylase 1AHomo sapiens (human)
transcription coactivator activityLysine-specific histone demethylase 1AHomo sapiens (human)
protein bindingLysine-specific histone demethylase 1AHomo sapiens (human)
oxidoreductase activityLysine-specific histone demethylase 1AHomo sapiens (human)
enzyme bindingLysine-specific histone demethylase 1AHomo sapiens (human)
nuclear receptor coactivator activityLysine-specific histone demethylase 1AHomo sapiens (human)
demethylase activityLysine-specific histone demethylase 1AHomo sapiens (human)
histone demethylase activityLysine-specific histone demethylase 1AHomo sapiens (human)
histone H3K4 demethylase activityLysine-specific histone demethylase 1AHomo sapiens (human)
histone H3K9 demethylase activityLysine-specific histone demethylase 1AHomo sapiens (human)
identical protein bindingLysine-specific histone demethylase 1AHomo sapiens (human)
MRF bindingLysine-specific histone demethylase 1AHomo sapiens (human)
flavin adenine dinucleotide bindingLysine-specific histone demethylase 1AHomo sapiens (human)
nuclear androgen receptor bindingLysine-specific histone demethylase 1AHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingLysine-specific histone demethylase 1AHomo sapiens (human)
telomeric repeat-containing RNA bindingLysine-specific histone demethylase 1AHomo sapiens (human)
DNA-binding transcription factor bindingLysine-specific histone demethylase 1AHomo sapiens (human)
FAD-dependent H3K4me/H3K4me3 demethylase activityLysine-specific histone demethylase 1AHomo sapiens (human)
promoter-specific chromatin bindingLysine-specific histone demethylase 1AHomo sapiens (human)
transcription factor bindingLysine-specific histone demethylase 1AHomo sapiens (human)
amyloid-beta bindingCholinesteraseHomo sapiens (human)
catalytic activityCholinesteraseHomo sapiens (human)
acetylcholinesterase activityCholinesteraseHomo sapiens (human)
cholinesterase activityCholinesteraseHomo sapiens (human)
protein bindingCholinesteraseHomo sapiens (human)
hydrolase activity, acting on ester bondsCholinesteraseHomo sapiens (human)
enzyme bindingCholinesteraseHomo sapiens (human)
choline bindingCholinesteraseHomo sapiens (human)
identical protein bindingCholinesteraseHomo sapiens (human)
RNA bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
zinc ion bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
enzyme bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
receptor tyrosine kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cadherin bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
ephrin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein phosphatase 2A bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
amyloid-beta bindingAcetylcholinesteraseHomo sapiens (human)
acetylcholinesterase activityAcetylcholinesteraseHomo sapiens (human)
cholinesterase activityAcetylcholinesteraseHomo sapiens (human)
protein bindingAcetylcholinesteraseHomo sapiens (human)
collagen bindingAcetylcholinesteraseHomo sapiens (human)
hydrolase activityAcetylcholinesteraseHomo sapiens (human)
serine hydrolase activityAcetylcholinesteraseHomo sapiens (human)
acetylcholine bindingAcetylcholinesteraseHomo sapiens (human)
protein homodimerization activityAcetylcholinesteraseHomo sapiens (human)
laminin bindingAcetylcholinesteraseHomo sapiens (human)
serine-type endopeptidase activityProlyl endopeptidaseHomo sapiens (human)
protein bindingProlyl endopeptidaseHomo sapiens (human)
serine-type peptidase activityProlyl endopeptidaseHomo sapiens (human)
oligopeptidase activityProlyl endopeptidaseHomo sapiens (human)
transcription coregulator bindingHistone acetyltransferase p300Homo sapiens (human)
transcription coactivator bindingHistone acetyltransferase p300Homo sapiens (human)
p53 bindingHistone acetyltransferase p300Homo sapiens (human)
DNA bindingHistone acetyltransferase p300Homo sapiens (human)
chromatin bindingHistone acetyltransferase p300Homo sapiens (human)
damaged DNA bindingHistone acetyltransferase p300Homo sapiens (human)
transcription coactivator activityHistone acetyltransferase p300Homo sapiens (human)
histone acetyltransferase activityHistone acetyltransferase p300Homo sapiens (human)
lysine N-acetyltransferase activity, acting on acetyl phosphate as donorHistone acetyltransferase p300Homo sapiens (human)
protein bindingHistone acetyltransferase p300Homo sapiens (human)
beta-catenin bindingHistone acetyltransferase p300Homo sapiens (human)
zinc ion bindingHistone acetyltransferase p300Homo sapiens (human)
histone H3 acetyltransferase activityHistone acetyltransferase p300Homo sapiens (human)
histone H4 acetyltransferase activityHistone acetyltransferase p300Homo sapiens (human)
acetyltransferase activityHistone acetyltransferase p300Homo sapiens (human)
acyltransferase activityHistone acetyltransferase p300Homo sapiens (human)
nuclear receptor bindingHistone acetyltransferase p300Homo sapiens (human)
peptide N-acetyltransferase activityHistone acetyltransferase p300Homo sapiens (human)
histone H3K18 acetyltransferase activityHistone acetyltransferase p300Homo sapiens (human)
histone H2B acetyltransferase activityHistone acetyltransferase p300Homo sapiens (human)
histone H3K27 acetyltransferase activityHistone acetyltransferase p300Homo sapiens (human)
tau protein bindingHistone acetyltransferase p300Homo sapiens (human)
nuclear androgen receptor bindingHistone acetyltransferase p300Homo sapiens (human)
NF-kappaB bindingHistone acetyltransferase p300Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingHistone acetyltransferase p300Homo sapiens (human)
peptide-lysine-N-acetyltransferase activityHistone acetyltransferase p300Homo sapiens (human)
protein propionyltransferase activityHistone acetyltransferase p300Homo sapiens (human)
pre-mRNA intronic bindingHistone acetyltransferase p300Homo sapiens (human)
STAT family protein bindingHistone acetyltransferase p300Homo sapiens (human)
peptide 2-hydroxyisobutyryltransferase activityHistone acetyltransferase p300Homo sapiens (human)
histone lactyltransferase activityHistone acetyltransferase p300Homo sapiens (human)
acetylation-dependent protein bindingHistone acetyltransferase p300Homo sapiens (human)
peptide butyryltransferase activityHistone acetyltransferase p300Homo sapiens (human)
histone crotonyltransferase activityHistone acetyltransferase p300Homo sapiens (human)
histone butyryltransferase activityHistone acetyltransferase p300Homo sapiens (human)
DNA-binding transcription factor bindingHistone acetyltransferase p300Homo sapiens (human)
histone H3K122 acetyltransferase activityHistone acetyltransferase p300Homo sapiens (human)
chromatin DNA bindingHistone acetyltransferase p300Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (33)

Processvia Protein(s)Taxonomy
chromatinLysine-specific histone demethylase 1AHomo sapiens (human)
nucleusLysine-specific histone demethylase 1AHomo sapiens (human)
chromosome, telomeric regionLysine-specific histone demethylase 1AHomo sapiens (human)
nucleusLysine-specific histone demethylase 1AHomo sapiens (human)
nucleoplasmLysine-specific histone demethylase 1AHomo sapiens (human)
transcription regulator complexLysine-specific histone demethylase 1AHomo sapiens (human)
protein-containing complexLysine-specific histone demethylase 1AHomo sapiens (human)
DNA repair complexLysine-specific histone demethylase 1AHomo sapiens (human)
extracellular regionCholinesteraseHomo sapiens (human)
nuclear envelope lumenCholinesteraseHomo sapiens (human)
endoplasmic reticulum lumenCholinesteraseHomo sapiens (human)
blood microparticleCholinesteraseHomo sapiens (human)
plasma membraneCholinesteraseHomo sapiens (human)
extracellular spaceCholinesteraseHomo sapiens (human)
plasma membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial matrixTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytosolTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial cristaTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endosome lumenTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
sorting endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmic side of endoplasmic reticulum membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein-containing complexTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
extracellular regionAcetylcholinesteraseHomo sapiens (human)
basement membraneAcetylcholinesteraseHomo sapiens (human)
extracellular spaceAcetylcholinesteraseHomo sapiens (human)
nucleusAcetylcholinesteraseHomo sapiens (human)
Golgi apparatusAcetylcholinesteraseHomo sapiens (human)
plasma membraneAcetylcholinesteraseHomo sapiens (human)
cell surfaceAcetylcholinesteraseHomo sapiens (human)
membraneAcetylcholinesteraseHomo sapiens (human)
neuromuscular junctionAcetylcholinesteraseHomo sapiens (human)
synaptic cleftAcetylcholinesteraseHomo sapiens (human)
synapseAcetylcholinesteraseHomo sapiens (human)
perinuclear region of cytoplasmAcetylcholinesteraseHomo sapiens (human)
side of membraneAcetylcholinesteraseHomo sapiens (human)
nucleusProlyl endopeptidaseHomo sapiens (human)
cytoplasmProlyl endopeptidaseHomo sapiens (human)
cytosolProlyl endopeptidaseHomo sapiens (human)
membraneProlyl endopeptidaseHomo sapiens (human)
cytosolProlyl endopeptidaseHomo sapiens (human)
cytoplasmHistone acetyltransferase p300Homo sapiens (human)
cytosolHistone acetyltransferase p300Homo sapiens (human)
nucleusHistone acetyltransferase p300Homo sapiens (human)
nucleoplasmHistone acetyltransferase p300Homo sapiens (human)
cytosolHistone acetyltransferase p300Homo sapiens (human)
chromatinHistone acetyltransferase p300Homo sapiens (human)
protein-DNA complexHistone acetyltransferase p300Homo sapiens (human)
transcription regulator complexHistone acetyltransferase p300Homo sapiens (human)
histone acetyltransferase complexHistone acetyltransferase p300Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (27)

Assay IDTitleYearJournalArticle
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID602156Novartis GNF Liver Stage Dataset: Malariabox Annotation2011Science (New York, N.Y.), Dec-09, Volume: 334, Issue:6061
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
AID1537276Inhibition of GSK3B (unknown origin) at 10 uM relative to control2019Journal of natural products, 02-22, Volume: 82, Issue:2
Isoquinoline Alkaloids from Berberis vulgaris as Potential Lead Compounds for the Treatment of Alzheimer's Disease.
AID1432742Cytotoxicity against mouse C2C12 cells at 10 nM up to 24 hrs2017Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6
Isoquinoline alkaloids from Coptis japonica stimulate the myoblast differentiation via p38 MAP-kinase and Akt signaling pathway.
AID1167294Inhibition of Clostridium perfringens neuraminidase 4-methylumbelliferyl-alpha-D-Nacetylneuraminic acid sodium salt hydrate as substrate by fluorometry2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
Neuraminidase inhibitory activities of quaternary isoquinoline alkaloids from Corydalis turtschaninovii rhizome.
AID1432743Induction of myoblast differentiation in mouse C2C12 cells expressing MyoD-responsive 4RTK-Luc assessed as increase in MHC protein expression at 10 nM after 2 days by Western blot analysis2017Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6
Isoquinoline alkaloids from Coptis japonica stimulate the myoblast differentiation via p38 MAP-kinase and Akt signaling pathway.
AID1537271Selectivity index, ratio of IC50 for human BuChE to IC50 for human AChE2019Journal of natural products, 02-22, Volume: 82, Issue:2
Isoquinoline Alkaloids from Berberis vulgaris as Potential Lead Compounds for the Treatment of Alzheimer's Disease.
AID1416210Inhibition of PTP1B (1 to 298 residues) (unknown origin) using DifMUP as substrate preincubated for 30 mins followed by substrate addition and measured after 30 mins by fluorescence assay2017MedChemComm, Jun-01, Volume: 8, Issue:6
PAIN-less identification and evaluation of small molecule inhibitors against protein tyrosine phosphatase 1B.
AID1537274Inhibition of POP (unknown origin) using (Z)-Gly-Pro-p-nitroanilide as substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by spectrophotometric method2019Journal of natural products, 02-22, Volume: 82, Issue:2
Isoquinoline Alkaloids from Berberis vulgaris as Potential Lead Compounds for the Treatment of Alzheimer's Disease.
AID1727405Inhibition of N-terminal His/GST-tagged human p300 HAT (965 to 1810 residues) expressed in Sf9 insect cells using H3 peptide as substrate in presence of Ac-CoA measured after 60 mins2021European journal of medicinal chemistry, Jan-01, Volume: 209Current development of CBP/p300 inhibitors in the last decade.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1910592Antiplatelet activity against ADP-induced C57BL/6J mouse platelet aggregation assessed as maximal aggregration rate at 10 uM preincubated for 10 mins followed by ADP addition relative to control2022Journal of medicinal chemistry, 05-26, Volume: 65, Issue:10
Palmatine Derivatives as Potential Antiplatelet Aggregation Agents via Protein Kinase G/Vasodilator-Stimulated Phosphoprotein and Phosphatidylinositol 3-Kinase/Akt Phosphorylation.
AID1167297Inhibition of Clostridium perfringens neuraminidase by Dixon plot2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
Neuraminidase inhibitory activities of quaternary isoquinoline alkaloids from Corydalis turtschaninovii rhizome.
AID1167295Inhibition of recombinant Influenza A virus H1N1 neuraminidase using 4-methylumbelliferyl-alpha-D-Nacetylneuraminic acid sodium salt hydrate as substrate by fluorometry2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
Neuraminidase inhibitory activities of quaternary isoquinoline alkaloids from Corydalis turtschaninovii rhizome.
AID1537277Permeability of the compound after 2.45 hrs by PAMPA2019Journal of natural products, 02-22, Volume: 82, Issue:2
Isoquinoline Alkaloids from Berberis vulgaris as Potential Lead Compounds for the Treatment of Alzheimer's Disease.
AID1167296Inhibition of Influenza A virus H5N1 neuraminidase using 4-methylumbelliferyl-alpha-D-Nacetylneuraminic acid sodium salt hydrate as substrate by fluorometry2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
Neuraminidase inhibitory activities of quaternary isoquinoline alkaloids from Corydalis turtschaninovii rhizome.
AID1432741Induction of MyoD transcriptional activity in mouse C2C12 cells expressing MyoD-responsive 4RTK-Luc at 10 nM after 24 hrs by luciferase reporter gene assay2017Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6
Isoquinoline alkaloids from Coptis japonica stimulate the myoblast differentiation via p38 MAP-kinase and Akt signaling pathway.
AID1537269Inhibition of human AChE using acetylthiocholine iodide as substrate measured for 1 min by Ellman's method2019Journal of natural products, 02-22, Volume: 82, Issue:2
Isoquinoline Alkaloids from Berberis vulgaris as Potential Lead Compounds for the Treatment of Alzheimer's Disease.
AID1845962Inhibition of recombinant LSD1 (unknown origin) expressed in Escherichia coli BL21 using H3K4me2 as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins by fluorescence based analysis2021European journal of medicinal chemistry, Mar-15, Volume: 214Annual review of LSD1/KDM1A inhibitors in 2020.
AID1416211Effect on fluorescence read out during PTP1B enzymatic reaction compound treated post enzyme-substrate reaction and susequent H2O2-mediated enzyme deactivation2017MedChemComm, Jun-01, Volume: 8, Issue:6
PAIN-less identification and evaluation of small molecule inhibitors against protein tyrosine phosphatase 1B.
AID1653971Cytotoxicity against human HaCaT cells assessed as reduction in cell viability after 24 hrs by MTT assay
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1167299Antibacterial activity against Clostridium perfringens in tryptic soy broth after 24 hrs2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
Neuraminidase inhibitory activities of quaternary isoquinoline alkaloids from Corydalis turtschaninovii rhizome.
AID1653955Inhibition of TNF-alpha/IFN-gamma-induced apoptosis in human HaCaT cells after 24 hrs by Annexin V-FITC/propidium iodide double staining-based flow cytometry
AID1537270Inhibition of human BuChE using butyrylthiocholine iodide as substrate measured for 1 min by Ellman's method2019Journal of natural products, 02-22, Volume: 82, Issue:2
Isoquinoline Alkaloids from Berberis vulgaris as Potential Lead Compounds for the Treatment of Alzheimer's Disease.
AID1168662Non-competitive inhibition of West Nile virus NS2B-NS3 protease2014European journal of medicinal chemistry, Nov-24, Volume: 87A perspective on targeting non-structural proteins to combat neglected tropical diseases: Dengue, West Nile and Chikungunya viruses.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (296)

TimeframeStudies, This Drug (%)All Drugs %
pre-199011 (3.72)18.7374
1990's19 (6.42)18.2507
2000's79 (26.69)29.6817
2010's138 (46.62)24.3611
2020's49 (16.55)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 41.60

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index41.60 (24.57)
Research Supply Index5.71 (2.92)
Research Growth Index5.13 (4.65)
Search Engine Demand Index58.27 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (41.60)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews8 (2.65%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other294 (97.35%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]